FGF23与缺血性脑卒中的关系及其相关 生物学机制
The Relationship between FGF23 and Ischemic Stroke and Related Biological Mechanisms
DOI: 10.12677/acm.2026.1652110, PDF,   
作者: 杨采妮, 李 迅：西安医学院研究生工作部，陕西 西安；毕 皎, 李雪萍*：西安医学院临床医学院，西安常见老年病防治重点实验室，陕西 西安
关键词: FGF23；缺血性脑卒中；血管内皮功能；动脉粥样硬化；FGF23； Ischemic Stroke； Vascular Endothelial Function； Atherosclerosis
摘要: 缺血性脑卒中是一种因颅内和颈动脉粥样硬化导致血流中断引发的脑组织损伤的疾病，已成为我国乃至全球成年人致死致残的最主要原因之一。成纤维细胞生长因子23 (Fibroblast growth factor 23, FGF23)是一种骨源性激素，其功能是抑制肾脏磷酸盐再吸收和维生素Ｄ合成，参与维持机体钙磷代谢平衡，病理条件下与心脑血管疾病密切相关。研究提示FGF23水平升高会影响血管内皮功能，加剧动脉粥样硬化和血管钙化程度，进而加速缺血性脑卒中的发生发展过程。因此，FGF23作为缺血性脑卒中潜在的预测因子及治疗靶点引起广泛关注，本文就FGF23对缺血性脑卒中的影响及相关生物学机制进行综述，以期为临床治疗和预防缺血性脑卒中带来新思路。
Abstract: Ischemic stroke (IS), a brain tissue injury characterized by the interruption of blood flow due to intracranial and carotid atherosclerosis, has become one of the leading causes of death and disability among adults both in China and worldwide. Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that suppresses renal phosphate reabsorption and vitamin D synthesis, thereby maintaining systemic calcium-phosphate homeostasis, and FGF23 is closely linked to cardiovascular and cerebrovascular diseases under pathological conditions. Emerging evidence indicated that elevated levels of FGF23 could impair vascular endothelial function, exacerbate atherosclerosis and vascular calcification, consequently accelerating the onset and progression of IS. Thus, FGF23 has attracted widespread attention as a potential predictive biomarker and therapeutic target for IS, this review summarized the influence of FGF23 on IS and its underlying biological mechanisms, aiming to provide novel insights for the clinical prevention and treatment of IS.
文章引用：杨采妮, 李迅, 毕皎, 李雪萍. FGF23与缺血性脑卒中的关系及其相关 生物学机制[J]. 临床医学进展, 2026, 16(5): 2968-2973. https://doi.org/10.12677/acm.2026.1652110

参考文献

[1] Tu, W., Zhao, Z., Yin, P., Cao, L., Zeng, J., Chen, H., et al. (2023) Estimated Burden of Stroke in China in 2020. JAMA Network Open, 6, e231455. [Google Scholar] [CrossRef] [PubMed]
[2] Cheng, F., Gao, H., Yan, B., Chen, F. and Lei, P. (2025) Triclosan Exposure Potentiates Ischemic Stroke Risk: Multi-Omics Integration and Molecular Docking Unveil Neurotoxic Mechanisms. Ecotoxicology and Environmental Safety, 302, Article 118551. [Google Scholar] [CrossRef] [PubMed]
[3] Abdalkader, M., Siegler, J.E., Lee, J.S., Yaghi, S., Qiu, Z., Huo, X., et al. (2023) Neuroimaging of Acute Ischemic Stroke: Multimodal Imaging Approach for Acute Endovascular Therapy. Journal of Stroke, 25, 55-71. [Google Scholar] [CrossRef] [PubMed]
[4] Adams, H.P., Bendixen, B.H., Kappelle, L.J., Biller, J., Love, B.B., Gordon, D.L., et al. (1993) Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 24, 35-41. [Google Scholar] [CrossRef] [PubMed]
[5] Gu, Z., Liu, J., Fu, J., et al. (2025) The Mechanism by Which FGF23/FGFR-1 Activates NOX2-ROS in Vascular Endothelial Cells in the Context of Severe Heat Stroke-Induced Acute Lung Injury. Burns Trauma, 13, tkae050. [Google Scholar] [CrossRef] [PubMed]
[6] Itoh, N. and Ornitz, D.M. (2011) Fibroblast Growth Factors: From Molecular Evolution to Roles in Development, Metabolism and Disease. The Journal of Biochemistry, 149, 121-130. [Google Scholar] [CrossRef] [PubMed]
[7] Ursem, S.R., Diepenbroek, C., Bacic, V., Unmehopa, U.A., Eggels, L., Maya-Monteiro, C.M., et al. (2021) Localization of Fibroblast Growth Factor 23 Protein in the Rat Hypothalamus. European Journal of Neuroscience, 54, 5261-5271. [Google Scholar] [CrossRef] [PubMed]
[8] Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., et al. (2001) Cloning and Characterization of FGF23 as a Causative Factor of Tumor-Induced Osteomalacia. Proceedings of the National Academy of Sciences, 98, 6500-6505. [Google Scholar] [CrossRef] [PubMed]
[9] Ho, B.B. and Bergwitz, C. (2021) FGF23 Signalling and Physiology. Journal of Molecular Endocrinology, 66, R23-R32. [Google Scholar] [CrossRef] [PubMed]
[10] Schjoldager, K.T., Vester-Christensen, M.B., Goth, C.K., et al. (2011) A Systematic Study of Site-Specific GalNAc-Type O-Glycosylation Modulating Proprotein Convertase Processing. Journal of Biological Chemistry, 286, 40122-40132. [Google Scholar] [CrossRef] [PubMed]
[11] Tagliabracci, V.S., Engel, J.L., Wiley, S.E., Xiao, J., Gonzalez, D.J., Nidumanda Appaiah, H., et al. (2014) Dynamic Regulation of FGF23 by Fam20C Phosphorylation, GalNAc-T3 Glycosylation, and Furin Proteolysis. Proceedings of the National Academy of Sciences, 111, 5520-5525. [Google Scholar] [CrossRef] [PubMed]
[12] Rausch, S. and Föller, M. (2022) The Regulation of FGF23 under Physiological and Pathophysiological Conditions. Pflügers Archiv—European Journal of Physiology, 474, 281-292. [Google Scholar] [CrossRef] [PubMed]
[13] Hanudel, M.R., Laster, M. and Salusky, I.B. (2018) Non-Renal-Related Mechanisms of FGF23 Pathophysiology. Current Osteoporosis Reports, 16, 724-729. [Google Scholar] [CrossRef] [PubMed]
[14] Chan, G.C., Divers, J., Russell, G.B., Langefeld, C.D., Wagenknecht, L.E., Hsu, F., et al. (2018) FGF23 Concentration and APOL1 Genotype Are Novel Predictors of Mortality in African Americans with Type 2 Diabetes. Diabetes Care, 41, 178-186. [Google Scholar] [CrossRef] [PubMed]
[15] Krüger-Genge, A., Blocki, A., Franke, R. and Jung, F. (2019) Vascular Endothelial Cell Biology: An Update. International Journal of Molecular Sciences, 20, Article 4411. [Google Scholar] [CrossRef] [PubMed]
[16] Lee, C.Y., Wu, S.W., Yang, J.J., et al. (2024) Vascular Endothelial Dysfunction Induced by 3-Bromofluoranthene via MAPK-Mediated-NF-κB Pro-Inflammatory Pathway and Intracellular ROS Generation. Archives of Toxicology, 98, 2247-2259. [Google Scholar] [CrossRef] [PubMed]
[17] Cocciolone, A.J., Hawes, J.Z., Staiculescu, M.C., Johnson, E.O., Murshed, M. and Wagenseil, J.E. (2018) Elastin, Arterial Mechanics, and Cardiovascular Disease. American Journal of Physiology-Heart and Circulatory Physiology, 315, H189-H205. [Google Scholar] [CrossRef] [PubMed]
[18] Silswal, N., Touchberry, C.D., Daniel, D.R., McCarthy, D.L., Zhang, S., Andresen, J., et al. (2014) FGF23 Directly Impairs Endothelium-Dependent Vasorelaxation by Increasing Superoxide Levels and Reducing Nitric Oxide Bioavailability. American Journal of Physiology-Endocrinology and Metabolism, 307, E426-E436. [Google Scholar] [CrossRef] [PubMed]
[19] Guo, L.W., Wang, Y.K., Li, S.J., Yin, G.T. and Li, D. (2023) Elevated Fibroblast Growth Factor 23 Impairs Endothelial Function through the NF-κB Signaling Pathway. Journal of Atherosclerosis and Thrombosis, 30, 138-149. [Google Scholar] [CrossRef] [PubMed]
[20] Mirza, M.A.I., Larsson, A., Lind, L. and Larsson, T.E. (2009) Circulating Fibroblast Growth Factor-23 Is Associated with Vascular Dysfunction in the Community. Atherosclerosis, 205, 385-390. [Google Scholar] [CrossRef] [PubMed]
[21] Libby, P., Ridker, P.M. and Hansson, G.K. (2009) Leducq Transatlantic Network on Atherothrombosis. Inflammation in Atherosclerosis: From Pathophysiology to Practice. Journal of the American College of Cardiology, 54, 2129-2138. [Google Scholar] [CrossRef] [PubMed]
[22] Freise, C., Jernej, T., Metzkow, S., Schnorr, J. and Taupitz, M. (2025) Fibroblast Growth Factor-23 Remodels Vascular Extracellular Matrix via Glycosaminoglycan Induction: Implications for Calcification in Chronic Kidney Disease. Renal Failure, 47, Article 2567528. [Google Scholar] [CrossRef] 
[23] Purnomo, E., Emoto, N., Nugrahaningsih, D.A.A., Nakayama, K., Yagi, K., Heiden, S., et al. (2013) Glycosaminoglycan Overproduction in the Aorta Increases Aortic Calcification in Murine Chronic Kidney Disease. Journal of the American Heart Association, 2, e000405. [Google Scholar] [CrossRef] [PubMed]
[24] Vogt, I., Haffner, D. and Leifheit-Nestler, M. (2019) FGF23 and Phosphate-Cardiovascular Toxins in CKD. Toxins, 11, Article 647. [Google Scholar] [CrossRef] [PubMed]
[25] Wungu, C.D.K., Susilo, H., Alsagaff, M.Y., Witarto, B.S., Witarto, A.P., Pakpahan, C., et al. (2024) Role of Klotho and Fibroblast Growth Factor 23 in Arterial Calcification, Thickness, and Stiffness: A Meta-Analysis of Observational Studies. Scientific Reports, 14, Article No. 5712. [Google Scholar] [CrossRef] [PubMed]
[26] Bi, J., Zheng, M., Li, K., Sun, S., Zhang, Z., Yan, N., et al. (2024) Relationships of Serum FGF23 and α-Klotho with Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Cardiovascular Diabetology, 23, Article No. 128. [Google Scholar] [CrossRef] [PubMed]
[27] Lutsey, P.L., Alonso, A., Selvin, E., Pankow, J.S., Michos, E.D., Agarwal, S.K., et al. (2014) Fibroblast Growth Factor-23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 3, e000936. [Google Scholar] [CrossRef] [PubMed]
[28] Marebwa, B.K., Adams, R.J., Magwood, G.S., Kindy, M., Wilmskoetter, J., Wolf, M., et al. (2018) Fibroblast Growth Factor23 Is Associated with Axonal Integrity and Neural Network Architecture in the Human Frontal Lobes. PLOS ONE, 13, e0203460. [Google Scholar] [CrossRef] [PubMed]
[29] 孟丽霞, 郗海涛, 申红梅. FGF23、ANGPTL4、Apelin-13与急性缺血性脑卒中患者病情及溶栓治疗短期预后的相关性[J]. 分子诊断与治疗杂志, 2024, 16(2): 308-312.
[30] Liu, M., Xia, P., Tan, Z., Song, T., Mei, K., Wang, J., et al. (2022) Fibroblast Growth Factor-23 and the Risk of Cardiovascular Diseases and Mortality in the General Population: A Systematic Review and Dose-Response Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article 989574. [Google Scholar] [CrossRef] [PubMed]
[31] Zheng, K., Lin, L., Cui, P., Liu, T., Chen, L., Yang, C., et al. (2020) Association of Fibroblast Growth Factor 23 with Ischemic Stroke and Its Subtypes: A Mendelian Randomization Study. Frontiers in Genetics, 11, Article 608517. [Google Scholar] [CrossRef] [PubMed]
[32] 李丹丹. 成纤维细胞生长因子23与缺血性脑卒中的相关性研究[D]: [硕士学位论文]. 延吉: 延边大学, 2019.
[33] Wright, C.B., Dong, C., Stark, M., Silverberg, S., Rundek, T., Elkind, M.S.V., et al. (2014) Plasma FGF23 and the Risk of Stroke: the Northern Manhattan Study (NO-MAS). Neurology, 82, 1700-1706. [Google Scholar] [CrossRef] [PubMed]
[34] Panwar, B., Jenny, N.S., Howard, V.J., Wadley, V.G., Muntner, P., Kissela, B.M., et al. (2015) Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults. Stroke, 46, 322-328. [Google Scholar] [CrossRef] [PubMed]
[35] Figurek, A., Rroji, M. and Spasovski, G. (2023) FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia. Cells, 12, Article 609. [Google Scholar] [CrossRef] [PubMed]
[36] Wright, C.B., Shah, N.H., Mendez, A.J., DeRosa, J.T., Yoshita, M., Elkind, M.S.V., et al. (2016) Fibroblast Growth Factor 23 Is Associated with Subclinical Cerebrovascular Damage: The Northern Manhattan Study. Stroke, 47, 923-928. [Google Scholar] [CrossRef] [PubMed]

为你推荐